Torbay Pharmaceuticals opens new £26 million pharmaceutical manufacturing unit
The new facilities enable to company to further grow and flourish.
Torbay Pharmaceuticals, part of Torbay and South Devon NHS Foundation Trust, has officially opened its new manufacturing unit in Paignton.
The Trust’s Chairman (Sir Richard Ibbotson), Managing Director (Emma Rooth), Technical Director (Mark Andrews), together with staff and other partners, marked the milestone with a celebratory opening ceremony with Sir Richard unveiling a commemorative plaque.
Sir Richard Ibbotson, Chairman of Torbay and South Devon NHS Foundation Trust, said: “We are incredibly proud of Torbay Pharmaceuticals and all that they have achieved over the years. Not only have they created a range of highly skilled career opportunities, but they generate income which directly supports the health and care of local people. This is a first-rate example of what innovation in the NHS can contribute to local communities.
“These fabulous new facilities offer a modern, class-leading environment which will enable Torbay Pharmaceuticals to further grow and flourish. I, on behalf of the Trust Board, cannot thank everyone enough for their hard work in seeing this superb project come to fruition.”
Emma Rooth, Managing Director of Torbay Pharmaceuticals, said: “Torbay Pharmaceuticals is proud to be such a successful part of Torbay and South Devon NHS Foundation Trust. Being part of the NHS enables us to have our finger on the pulse of healthcare needs and respond appropriately with new products, plugging shortages and anticipating the latest developments in medical science.
“Since the establishment of the original pharmaceutical department at Torbay Hospital back in the 1970s, we have grown from strength to strength to meet not only our local population’s needs, but also the needs of the wider NHS and healthcare providers globally.
“The official opening of our new class-leading sterile product facility is a very exciting time for Torbay Pharmaceuticals. By strengthening our production capabilities and ensuring the delivery of high-quality products for our patients through this investment, we have created the platform upon which we can achieve significant growth for the organisation, its people and the region.”
Bryan Taylor, UK Property Director for Balfour Beatty, said: “The official opening of Torbay Pharmaceuticals new manufacturing unit in Paignton marks the completion of 8 years of involvement by Balfour Beatty. Having secured the plot, designed, developed and constructed the facility, the project reflects the all-encompassing skills, expertise and capabilities of Balfour Beatty in providing clients with whole project life cycle solutions.”
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance